2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 | 新 已发表SCI？是时候来Springer出书了！ |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Antibody Therapeutics （此期刊被最新的JCR期刊ESCI收录） LetPub评分 3.3
50人评分
我要评分
声誉 3.7 影响力 2.3 速度 7.0 | |||||||||||||||||||||
| 期刊ISSN | 2516-4236 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||
| 实时影响因子 | - | |||||||||||||||||||||
| 2025-2026自引率 | 4.2%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 0数据由网友[随意清澈]收集提供 | |||||||||||||||||||||
| h-index | 暂无h-index数据 | |||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | https://academic.oup.com/abt | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | ||||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Application of a novel LC-MS-based proteomic workflow for host cell protein monitoring and risk control in biotherapeutics Author: Yu, Xiaojuan; Cheng, Jianhui; Lv, Qianchuan; Wang, Feiyu; Hu, Jianzhong; Li, Xinxin; Yu, Chuanfei Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 159-167. DOI: 10.1093/abt/tbag013 Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T Author: Yang, Ting; Gao, Min; Sun, Yufang; Li, Zhiwei; Xie, Zijun; Zou, Ming; Deng, Mi Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 150-158. DOI: 10.1093/abt/tbag010 Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond Author: Wang, Li-Min; Yang, Changyong; Chen, Simeng; Sun, Xing; Tian, Yunan; Zhang, Jieqiong; Gao, Xiaomeng; Li, Dan; Zhang, Wei; Hu, Yali; Yuan, Jimin; Xu, Qumiao; Liu, Xiyang; Zhang, Long; Yu, Qianqian; Liao, Cheng Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 201-213. DOI: 10.1093/abt/tbag015 Preclinical characterization of IBD0333, a novel CD24×4-1BB bispecific antibody with tumor-dependent agonistic activity for cancer immunotherapy Author: Jiang, Dong-Cheng; Zhou, Dan-Dan; Xu, Xiao-Rui; Jiang, Xiao-Ling; Yin, Liu-Song; Zhong, Cai-Yun; Miao, Qing-Fang Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 168-178. DOI: 10.1093/abt/tbag014 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Antibody Therapeutics的语言要求，还能让Antibody Therapeutics编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Antibody Therapeutics编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD2687; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：therapeutics、pharmacology、antibodies 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||
| 通讯方式 | ||||||||||||||||||||||
| 出版商 | Oxford University Press | |||||||||||||||||||||
| 涉及的研究方向 | Medicine-Immunology and Allergy | |||||||||||||||||||||
| 出版国家或地区 | United Kingdom | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||
| 年文章数 | 27点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 55.56% | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） | （没有被2025年的期刊分区表收录，仅供参考） | |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） | （没有被旧的期刊分区表收录，仅供参考） | |||||||||||||||||||||
| SCI期刊收录coverage | Emerging Sources Citation Index (ESCI) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2516-4236%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 8 Weeks | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ USD2687; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Antibody Therapeutics顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
| |
| 中国学者近期发表的论文 | |
| 1. | Application of a novel LC-MS-based proteomic workflow for host cell protein monitoring and risk control in biotherapeutics Author: Yu, Xiaojuan; Cheng, Jianhui; Lv, Qianchuan; Wang, Feiyu; Hu, Jianzhong; Li, Xinxin; Yu, Chuanfei Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 159-167. DOI: 10.1093/abt/tbag013 PubMed DOI |
| 2. | Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T Author: Yang, Ting; Gao, Min; Sun, Yufang; Li, Zhiwei; Xie, Zijun; Zou, Ming; Deng, Mi Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 150-158. DOI: 10.1093/abt/tbag010 PubMed DOI |
| 3. | Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond Author: Wang, Li-Min; Yang, Changyong; Chen, Simeng; Sun, Xing; Tian, Yunan; Zhang, Jieqiong; Gao, Xiaomeng; Li, Dan; Zhang, Wei; Hu, Yali; Yuan, Jimin; Xu, Qumiao; Liu, Xiyang; Zhang, Long; Yu, Qianqian; Liao, Cheng Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 201-213. DOI: 10.1093/abt/tbag015 DOI |
| 4. | Preclinical characterization of IBD0333, a novel CD24×4-1BB bispecific antibody with tumor-dependent agonistic activity for cancer immunotherapy Author: Jiang, Dong-Cheng; Zhou, Dan-Dan; Xu, Xiao-Rui; Jiang, Xiao-Ling; Yin, Liu-Song; Zhong, Cai-Yun; Miao, Qing-Fang Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 168-178. DOI: 10.1093/abt/tbag014 PubMed DOI |
| 5. | Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy Author: Dong, Cunnan; Wang, Xue Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 191-200. DOI: 10.1093/abt/tbag016 PubMed DOI |
| 6. | Durable disease control following treatment with ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, in femoral osteosarcoma with lung metastases after chemotherapy failure: a case report Author: Xie, Xianbiao; Bian, Yiying; Yang, Xiugao; Zhang, Yanfeng; Yin, Junqiang; Shen, Jingnan Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 119-124. DOI: 10.1093/abt/tbag007 PubMed DOI |
| 7. | Challenges and solutions for upstream processing of complex biologics Author: Xu, Shuya; Wang, Yunlong; Yu, Yawen; Zhu, Felix; Li, Ying Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 2, pp. 139-149. DOI: 10.1093/abt/tbag008 PubMed DOI |
| 8. | A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis Author: Zhang, Qun; Song, Shuliang Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 1, pp. 76-85. DOI: 10.1093/abt/tbag003 PubMed DOI |
| 9. | IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy Author: Chen, Dianze; Wu, Zhuli; Zhao, Xiwen; Bhatt, Rupal S.; Yang, Yanan; Zhu, Wenqi; Tang, Huang; Wang, Kaili; Guo, Chunli; Liu, Dandan; Yang, Chunmei; Guo, Huiqin; Bai, Xing; Zhang, Ruliang; Li, Song; Tian, Wenzhi Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 1, pp. 86-99. DOI: 10.1093/abt/tbag002 PubMed DOI |
| 10. | Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy Author: Kang, Xiaoqiang; Zhao, Yue; Ling, Hong; Huang, Xiao Journal: ANTIBODY THERAPEUTICS. 2026; Vol. 9, Issue 1, pp. 58-69. DOI: 10.1093/abt/tbaf026 PubMed DOI |
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共0条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
